<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001634'>Mitral valve prolapse</z:hpo> (MVP) is a common human phenotype, yet little is known about the pathogenesis of this condition </plain></SENT>
<SENT sid="1" pm="."><plain>MVP can occur in the context of <z:e sem="disease" ids="C0567439" disease_type="Disease or Syndrome" abbrv="">genetic syndromes</z:e>, including <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>), an <z:hpo ids='HP_0000006'>autosomal-dominant</z:hpo> <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> caused by mutations in fibrillin-1 </plain></SENT>
<SENT sid="2" pm="."><plain>Fibrillin-1 contributes to the regulated activation of the cytokine TGF-beta, and enhanced signaling is a consequence of fibrillin-1 deficiency </plain></SENT>
<SENT sid="3" pm="."><plain>We thus hypothesized that increased TGF-beta signaling may contribute to the multisystem pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, including the development of myxomatous changes of the atrioventricular valves </plain></SENT>
<SENT sid="4" pm="."><plain>Mitral valves from fibrillin-1-deficient mice exhibited postnatally acquired alterations in architecture that correlated both temporally and spatially with <z:mp ids='MP_0000351'>increased cell proliferation</z:mp>, <z:mp ids='MP_0006043'>decreased apoptosis</z:mp>, and excess TGF-beta activation and signaling </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, TGF-beta antagonism in vivo rescued the valve phenotype, suggesting a cause and effect relationship </plain></SENT>
<SENT sid="6" pm="."><plain>Expression analyses identified increased expression of numerous TGF-beta-related genes that regulate cell proliferation and survival and plausibly contribute to myxomatous valve disease </plain></SENT>
<SENT sid="7" pm="."><plain>These studies validate a novel, genetically engineered murine model of myxomatous changes of the mitral valve and provide critical insight into the pathogenetic mechanism of such changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and perhaps more common nonsyndromic variants of <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> </plain></SENT>
</text></document>